Mallinckrodt and MBI file PMA for FS069
Mallinckrodt Medical and Molecular Biosystems have filed a premarketapproval (PMA) application for cardiac uses of MBI's second-generationFS069 ultrasound contrast agent. The companies said the PMA coversclinical studies in which FS069 was used for
Mallinckrodt Medical and Molecular Biosystems have filed a premarketapproval (PMA) application for cardiac uses of MBI's second-generationFS069 ultrasound contrast agent. The companies said the PMA coversclinical studies in which FS069 was used for enhancing endocardialborder delineation, as well as opacification of the left ventricularchamber. Doppler signal enhancement was also studied.
San Diego-based MBI is developing FS069 and has granted licensingrights for the agent to Mallinckrodt of St. Louis for North andSouth America, China, Australia, and New Zealand (SCAN 9/13/95).Both parties are hoping the agent will prove more successful thanAlbunex, MBI's first-generation agent, which has received a tepidresponse from the ultrasound community since it was introducedin 1994. Mallinckrodt also markets Albunex.
A phase III clinical trial conducted for FS069's PMA comparedthe agent with Albunex, and demonstrated the newer agent's superiorityin providing endocardial border delineation as well as left ventricularcontrast enhancement, both of which improve visualization of cardiac-wallmotion and function.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
